ImmunityBio/$IBRX
1D1W1MYTD1Y5YMAX
Capital at risk
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Ticker
- $IBRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 688
- Headquarters
- San Diego, United States
- Website
- immunitybio.com
ImmunityBio Metrics
BasicAdvanced
$8.6B
-
-$0.99
0.13
-
Price and volume
Market cap
$8.6B
Beta
0.13
52-week high
$12.43
52-week low
$1.95
Average daily volume
8.3M
Financial strength
Current ratio
5.721
Quick ratio
5.355
Long term debt to equity
-1.167
Total debt to equity
-1.175
Interest coverage (TTM)
-2.20%
Profitability
EBITDA (TTM)
-235.298
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-598.56%
Operating margin (TTM)
-151.88%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-30.54%
Return on equity (TTM)
122.86%
Valuation
Price to revenue (TTM)
49.281
Price to book
-8.19
Price to tangible book (TTM)
-8.1
Price to free cash flow (TTM)
-28.319
Free cash flow yield (TTM)
-3.53%
Free cash flow per share (TTM)
-0.287
Growth
Revenue change (TTM)
192.92%
Earnings per share change (TTM)
104.25%
3-year revenue growth (CAGR)
554.26%
3-year earnings per share growth (CAGR)
-4.55%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Analyst projections of the future price of ImmunityBio stock.
Bulls say / Bears say
Record Q2 2026 net product revenue of $50.7 million, up 92% YoY, and first-half revenue of $94.8 million, up 121% YoY, marking the eighth consecutive quarter of sequential growth since ANKTIVA’s launch (Nasdaq).
European Commission granted conditional marketing authorization for ANKTIVA® with BCG in non-muscle invasive bladder cancer in February 2026, expanding access to 30 EU member states plus Iceland, Norway, and Liechtenstein (33 countries total) (EUR-LEX).
FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA® plus BCG in BCG-unresponsive papillary NMIBC, setting a PDUFA target action date of January 6, 2027, positioning the company for potential label expansion (Reuters).
GAAP net loss widened to $230.4 million in Q2 2026 from $92.6 million a year earlier, driven by elevated R&D spending and $147.7 million in other expense due to non-cash fair-value adjustments, underscoring continued cash burn (Nasdaq).
Under its RIPA financing agreement, ImmunityBio must pay tiered revenue interest payments ranging from 5.625% to 12.5% on net product sales until capped at 195% of purchase payments, which may compress future margins and cash flow (SEC).
Regulatory uncertainty persists after FDA issued an inconsistent refusal to file letter in May 2025 for the papillary NMIBC sBLA, highlighting risk ahead of the January 2027 PDUFA decision (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
ImmunityBio News
AllArticlesVideos
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
Business Wire1 month ago
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
Business Wire2 months ago
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Benzinga2 months ago
Funds containing ImmunityBio
AllUSDGBPEUR
Fund name | Fund size | $IBRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.58% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.58% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.31% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.31% |
iShares Healthcare Innovation£DRDR | £1B | 0.31% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.